Colorectal carcinoma (CRC) ranks as the fourth most prevalent malignancy globally.
Neuromedin B (NMB) and its corresponding receptor have been implicated in the pathogenesis of multiple neoplastic conditions.
Nevertheless, the specific involvement of NMB in CRC progression remains poorly characterized.
